Seeking Alpha

Gilead Sciences (GILD -1.3%) says Phase 3 clinical trial results from its study comparing single...

Gilead Sciences (GILD -1.3%) says Phase 3 clinical trial results from its study comparing single tablet regimens of Complera versus Atripla in adults with HIV infection demonstrated that Complera - which is marketed as Eviplera in the E.U. - showed a statistically significant difference in efficacy compared to Atripla among patients with low baseline viral load, and was non-inferior to Atripla among patients with high baseline viral load. Separately, the company also reports that two-year results from two Phase 3 tests of it's newest single tablet HIV regimen, Stribild, also showed it was non-inferior after two years of treatment as compared to two other standard HIV regimens.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs